Clinical Trial Update: Targeted Pathway Inhibition in Patients With Pancreatic Cancer [EARLY_Phase 1]

View source ↗

Summary

An early-phase (Phase 1) trial of a targeted pathway inhibitor for pancreatic ductal adenocarcinoma is currently recruiting, enrolling patients with locally adv…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Ductal Adenocarcinoma

Snippet

Sponsor: OHSU Knight Cancer Institute | Conditions: Locally Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma | EARLY_Phase 1 | Status: RECRUITING